Aim: To investigate the SLCO1B1 388A>G and 521T>C polymorphisms in hyperlipidemia patients and evaluate the effect of the two polymorphisms on the lipid-lowering efficacy of pitavastatin. Methods: The functional polymorphisms of SLCO1B1 (388A>G and 521T>C) were genotyped in 140 Chinese patients with essential hyperlipidemia using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and one-step tetra-primers ARMS-PCR. Eighty-five patients were enrolled in the clinical trial and given 2 mg of pitavastatin daily for 8 weeks. Total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), and low-density lipoprotein (LDL) serum levels were measured at baseline, after 4 weeks and after 8 weeks of treatment. Results: The allele frequencies of SLCO1B1 388A>G and 521T>C in essential hyperlipidemia patients were 71.1% and 11.1%, respectively. The 4-and 8-week treatment with pitavastatin significantly reduced TC, TG, and LDL levels, but there was no statistical difference among patients with wild type, SLCO1B1 388A>G or SLCO1B1 521T>C in the lipid-lowering efficacy of pitavastatin. Conclusion: The present study found that the allele frequencies of SLCO1B1 388A>G and 521T>C in Chinese patients with essential hyperlipidemia are comparable to those in healthy Chinese population. SLCO1B1 388A>G and 521T>C do not affect the lipid-lowering efficacy of pitavastatin.
Introduction
The organic anion transporting polypeptide 1B1 (OATP1B1, also known as OATP-C, OATP2, and LST-1), exclusively expressed in the basolateral membrane of hepatocytes [1] is an important transporter of the OATP family, which contributes to the hepatic uptake of many endogenous and xenobiotic compounds including bile acids, sulfate and glucuronide conjugates, thyroid hormones, peptides and drugs such as pravastatin, pitavastatin, methotrexate and rifampin [2] .
The highly polymorphic gene SLCO1B1 encodes OATP1B1: to date, more than 20 single nucleotide polymorphisms (SNPs) have been identified, some of which are associated with altered function. SLCO1B1 388A>G (Asn130Asp) and 521T>C (Val174Ala) are common variants and have altered transport activities in vitro. In addition, cumulative evidence indicates that SLCO1B1 polymorphisms can significantly affect the pharmacokinetics of statins.
Pitavastatin (p-INN) is a novel synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA) inhibitor. It has a stronger hypolipidemic profile and a safer profile than other statins, and may be a better choice for treatment of hypercholesterolemic patients [3] . In vivo, pitavastatin is scarcely metabolized by cytochrome P450 2C9 and undergoes reversible lactonization [3, 4] . OATP1B1 is a transporter in the liver and plays an important role in the distribution of pitavastatin [5] .
Some research [6] [7] [8] indicates that SLCO1B1 polymorphisms www.chinaphar.com Yang GP et al Acta Pharmacologica Sinica npg have significant effects on the pharmacokinetics of pitavastatin. The dose-normalized area under the plasma concentration-time curve (AUC) and peak plasma concentration (C max ) values of pitavastatin in heterozygous subjects of SLCO1B1*15 (388A>G and 521T>C) or 521T>C were 1.4-and 1.8-fold higher, respectively, than in subjects without these SNPs [7] . SLCO1B1 polymorphisms had greater effects on the pharmacokinetic parameters of pitavastatin than those previously reported in pravastatin [8] . In addition, recent studies [9] [10] [11] [12] reported that SLCO1B1 polymorphisms were associated with the lipidlowering response to HMG-CoA inhibitors and adverse effects of simvastatin and irinotecan. The present study was conducted to investigate the contribution of the SLCO1B1 388A>G and 521T>C polymorphisms to inter-individual response to pitavastatin in Chinese primary hyperlipidemia patients. Clinical trial protocol Subjects were treated with 2 mg of pitavastatin once daily after supper for 8 weeks. TC, TG, HDL, and low-density lipoprotein (LDL) plasma concentrations were determined at 0, 4, and 8 weeks of treatment. Vital signs, hepatic function, renal function, creatine kinase levels, fasting blood glucose levels and adverse events were monitored in safety evaluations.
Materials and methods

Subjects
Genotyping
Venous blood (5 mL) was collected from patients in a sterile tube containing EDTA and stored at 4 °C. Genomic DNA was extracted by the QIAamp whole blood mini kit (Qiagen) following the manufacturer's instructions. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was performed for 388G>A genotyping, and an amplification refractory mutation system (ARMS-PCR) was used for 521T>C genotyping as previously described [13] .
Statistical analysis
Genotype frequencies of SLCO1B1 388G>A and 521T>C were assessed for deviation from Hardy-Weinberg equilibrium using the χ 2 -test of goodness-of-fit. Differences between lipid parameters before and after pitavastatin treatment were tested using the paired t-test. Potential differences in drug response among the genotypes were tested using a one-way analysis of variance (ANOVA). The statistical significance level was defined as a P-value of less than 0.05 and statistical calculations were performed using the SPSS software (SPSS 11.0 for Windows; SPSS Inc, Chicago, IL). 
Results
Allelic frequencies of SLCO1B1 SNPs
Discussion
SLCO1B1 is a newly identified transporter with functional genetic polymorphisms. Based on the functional variability of OATP1B1 and its broad range of substrates, SNPs in SLCO1B1 may play an important role in pharmacology and toxicology. One such polymorphism, 521T>C, has been consistently associated with altered transport activity both in vitro [14, 15] and in vivo [7] [8] [9] [16] [17] [18] though results regarding the 388G>A variant are contradictory [14, 15, 19, 20] . In the present study, the allele frequencies of 521C (11.1%) and 388A (71.1%) in Chinese primary hyperlipidemia patients were similar to those previously reported in healthy Chinese populations [13] . These results indicate that SLCO1B1 388G>A and 521T>C variants are not associated with primary hyperlipidemia, although SLCO1B1 has been reported to be involved in the transportation of cholesterol and statins. Recent studies [7] [8] [9] [21] [22] [23] [24] consistently showed SLCO1B1 variants altered the pharmacokinetics of pitavastatin, rosuvastatin, simvastatin acid, atorvastatin and pravastatin, but our data revealed that there was no significant difference in therapeutic effect of pitavastatin among various genotypes. Interestingly, the alteration of pharmacokinetics did not extend to the response to pitavastatin. Similar results were also obtained for other statins in separate studies [24, 25] : the plasma concentration of pravastatin in subjects with haplotypes *15 or *17 (11187G>A, 388A>G, and 521T>C) was higher than in wild- npg type subjects when they were given 40 mg of pravastatin daily for 3 weeks, but there was no statistical difference in the lipidlowering efficacy between genotypes [24] .
In vivo, part of pitavastatin is reversibly converted to a lactone form, and the disposition of pitavastatin lactone is different from that of the parent drug. Chung et al [7] reported that SLCO1B1 521T>C and 388G>A were not associated with a change in the pharmacokinetics of pitavastatin lactone. In addition, the alteration of pharmacokinetics due to polymorphisms in SLCO1B1 may not be sufficient to affect the pharmacodynamics of pitavastatin. Takane et al [26] reported that the SLCO1B1*15 allele was associated with a slow response to pravastatin therapy, and the combined genotype of CYP7A1 and APOE was a more useful index to predict the lipid-lowering effect of pravastatin. This implies that polymorphisms in other genes may play an important role in inter-individual variable response to statins.
In conclusion, the present study found that allele frequencies of SLCO1B1 388G>A and 521T>C in patients with essential hyperlipidemia were comparable to those in healthy Chinese population and there was no significant difference in the lipidlowering efficacy of pitavastatin among various genotype groups.
